Literature DB >> 19277685

Receptor for advanced glycation end products is upregulated in optic neuropathy of Alzheimer's disease.

Michelle Y Wang1, Fred N Ross-Cisneros, Divya Aggarwal, Chiao-Ying Liang, Alfredo A Sadun.   

Abstract

Although Alzheimer's disease (AD) has been shown to be associated with a true primary optic neuropathy, the underlying pathophysiology of this disease and in particular the optic nerve disorder is still poorly understood. The receptor for advanced glycation end products (RAGE) has been implicated in the pathogenesis of AD by mediating the transport of plasma amyloid-beta into the brain. Once ligated, RAGE can play a role in signal transduction, leading to amplification and perpetuation of inflammatory processes. As a key player in the reaction to CNS injury, astrocytes have been shown to associate with RAGE in a number of diseases, including AD. To investigate the role of RAGE and astrocytes in the pathogenesis of AD optic neuropathy, we conducted immunohistochemical studies to examine the presence of RAGE in donor eyes from patients with AD (n = 10) and controls (n = 3). Both qualitative observation and quantitative analyses using imaging software were used to document the extent of RAGE in the neural tissues. The intensity and extent of RAGE expression was more prominent in AD nerves compared to controls (P < 0.05). The RAGE immunoreactivity was observed in the microvasculature and in close proximity to astrocytic processes. While RAGE immunoreactivity increased with age, the increase was more precipitous in the AD group compared to the controls. The up-regulation of RAGE in the AD optic nerves indicates that RAGE may play a role in the pathophysiology of AD optic neuropathy.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19277685      PMCID: PMC2867613          DOI: 10.1007/s00401-009-0513-4

Source DB:  PubMed          Journal:  Acta Neuropathol        ISSN: 0001-6322            Impact factor:   17.088


  37 in total

Review 1.  Ophthalmologic manifestations of Alzheimer's disease.

Authors:  B Katz; S Rimmer
Journal:  Surv Ophthalmol       Date:  1989 Jul-Aug       Impact factor: 6.048

2.  Assessment of visual impairment in patients with Alzheimer's disease.

Authors:  A A Sadun; M Borchert; E DeVita; D R Hinton; C J Bassi
Journal:  Am J Ophthalmol       Date:  1987-08-15       Impact factor: 5.258

3.  Glial fibrillary acidic protein and Alzheimer-type senile dementia.

Authors:  P E Duffy; M Rapport; L Graf
Journal:  Neurology       Date:  1980-07       Impact factor: 9.910

Review 4.  Clearing amyloid through the blood-brain barrier.

Authors:  Berislav V Zlokovic
Journal:  J Neurochem       Date:  2004-05       Impact factor: 5.372

5.  Optic-nerve degeneration in Alzheimer's disease.

Authors:  D R Hinton; A A Sadun; J C Blanks; C A Miller
Journal:  N Engl J Med       Date:  1986-08-21       Impact factor: 91.245

6.  RAGE potentiates Abeta-induced perturbation of neuronal function in transgenic mice.

Authors:  Ottavio Arancio; Hui Ping Zhang; Xi Chen; Chang Lin; Fabrizio Trinchese; Daniela Puzzo; Shumin Liu; Ashok Hegde; Shi Fang Yan; Alan Stern; John S Luddy; Lih-Fen Lue; Douglas G Walker; Alex Roher; Manuel Buttini; Lennart Mucke; Weiying Li; Ann Marie Schmidt; Mark Kindy; Paul A Hyslop; David M Stern; Shirley Shi Du Yan
Journal:  EMBO J       Date:  2004-09-30       Impact factor: 11.598

7.  The optic neuropathy of Alzheimer's disease.

Authors:  A A Sadun
Journal:  Metab Pediatr Syst Ophthalmol (1985)       Date:  1989

8.  Alzheimer's disease. A double-labeling immunohistochemical study of senile plaques.

Authors:  D W Dickson; J Farlo; P Davies; H Crystal; P Fuld; S H Yen
Journal:  Am J Pathol       Date:  1988-07       Impact factor: 4.307

9.  Autoimmunity in Alzheimer's disease: increased levels of circulating IgGs binding Abeta and RAGE peptides.

Authors:  Shyamala Mruthinti; Jerry J Buccafusco; William D Hill; Jennifer L Waller; Thomas W Jackson; Edward Y Zamrini; Rosann F Schade
Journal:  Neurobiol Aging       Date:  2004-09       Impact factor: 4.673

10.  Brain interleukin 1 and S-100 immunoreactivity are elevated in Down syndrome and Alzheimer disease.

Authors:  W S Griffin; L C Stanley; C Ling; L White; V MacLeod; L J Perrot; C L White; C Araoz
Journal:  Proc Natl Acad Sci U S A       Date:  1989-10       Impact factor: 11.205

View more
  12 in total

1.  Aging-related changes of optic nerve of Wistar albino rats.

Authors:  Hassan I H El-Sayyad; Soad A Khalifa; Fawkia I El-Sayyad; Asma S Al-Gebaly; Ahmed A El-Mansy; Ezaldin A M Mohammed
Journal:  Age (Dordr)       Date:  2013-09-01

2.  Low-density lipoprotein receptor-related protein is decreased in optic neuropathy of Alzheimer disease.

Authors:  Lloyd M Cuzzo; Fred N Ross-Cisneros; Kenneth M Yee; Michelle Y Wang; Alfredo A Sadun
Journal:  J Neuroophthalmol       Date:  2011-06       Impact factor: 3.042

Review 3.  The Beneficial Role of Exercise on Treating Alzheimer's Disease by Inhibiting β-Amyloid Peptide.

Authors:  Zi-Xuan Tan; Fang Dong; Lin-Yu Wu; Ya-Shuo Feng; Feng Zhang
Journal:  Mol Neurobiol       Date:  2021-08-20       Impact factor: 5.590

Review 4.  Role of RAGE in the Pathogenesis of Neurological Disorders.

Authors:  Judyta Juranek; Konark Mukherjee; Bernard Kordas; Michał Załęcki; Agnieszka Korytko; Kamila Zglejc-Waszak; Jarosław Szuszkiewicz; Marta Banach
Journal:  Neurosci Bull       Date:  2022-06-21       Impact factor: 5.271

Review 5.  Too sweet: Problems of protein glycation in the eye.

Authors:  Eloy Bejarano; Allen Taylor
Journal:  Exp Eye Res       Date:  2018-08-24       Impact factor: 3.467

Review 6.  Recent advances in our understanding of neurodegeneration.

Authors:  Kurt A Jellinger
Journal:  J Neural Transm (Vienna)       Date:  2009-06-05       Impact factor: 3.575

Review 7.  One protein, multiple pathologies: multifaceted involvement of amyloid β in neurodegenerative disorders of the brain and retina.

Authors:  Vivek Gupta; Veer B Gupta; Nitin Chitranshi; Sumudu Gangoda; Roshana Vander Wall; Mojdeh Abbasi; Mojtaba Golzan; Yogita Dheer; Tejal Shah; Alberto Avolio; Roger Chung; Ralph Martins; Stuart Graham
Journal:  Cell Mol Life Sci       Date:  2016-06-22       Impact factor: 9.261

8.  Effect of dietary advanced glycation end products on mouse liver.

Authors:  Raza Patel; Susan S Baker; Wensheng Liu; Sonal Desai; Razan Alkhouri; Rafal Kozielski; Lucy Mastrandrea; Adil Sarfraz; Weijing Cai; Helen Vlassara; Mulchand S Patel; Robert D Baker; Lixin Zhu
Journal:  PLoS One       Date:  2012-04-04       Impact factor: 3.240

9.  Receptor for Advanced Glycation End Products and its Inflammatory Ligands are Upregulated in Amyotrophic Lateral Sclerosis.

Authors:  Judyta K Juranek; Gurdip K Daffu; Joanna Wojtkiewicz; David Lacomis; Julia Kofler; Ann Marie Schmidt
Journal:  Front Cell Neurosci       Date:  2015-12-22       Impact factor: 5.505

Review 10.  Basic mechanisms of neurodegeneration: a critical update.

Authors:  Kurt A Jellinger
Journal:  J Cell Mol Med       Date:  2010-01-11       Impact factor: 5.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.